Milestone Pharmaceuticals
MIST
47 hedge funds and large institutions have $57.9M invested in Milestone Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
33% more capital invested
Capital invested by funds: $43.6M → $57.9M (+$14.4M)
9% more funds holding
Funds holding: 43 → 47 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
7.8% less ownership
Funds ownership: 53.83% → 46.04% (-7.8%)
45% less call options, than puts
Call options by funds: $144K | Put options by funds: $264K
Top Buyers
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$1.29M |
| 2 |
Morgan Stanley
New York
|
+$637K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$154K |
| 4 |
VF
Virtu Financial
New York
|
+$124K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$90.4K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.49M |
| 2 |
BlackRock
New York
|
-$1.58M |
| 3 |
RI
RTW Investments
New York
|
-$1.29M |
| 4 |
LPC
Lion Point Capital
New York
|
-$1.08M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$858K |
MIST Hedge Fund Activity: Q4 2024 in Review
47 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2024, worth a combined $57.9M — up 33% from $43.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MIST positions and 6 closed out — a net gain of 4 holders — while 14 added to existing stakes and 14 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $1.29M. The largest seller was Citadel Advisors, cutting an estimated $2.49M.
- 47 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2024, up from 43 in Q3 2024.
- Funds reported $57.9M of Milestone Pharmaceuticals stock for Q4 2024, up 33% quarter-over-quarter.
- 10 funds opened new Milestone Pharmaceuticals positions in Q4 2024 and 6 closed out, a net change of +4 holders.
- The largest Milestone Pharmaceuticals buyer in Q4 2024 was Toronto Dominion Bank, an estimated $1.29M added.
- The largest Milestone Pharmaceuticals seller in Q4 2024 was Citadel Advisors, an estimated $2.49M sold.
Based on aggregated 13F filings for Q4 2024.